^
    Back
    Association details:
    Biomarker:ALK G1269A
    Cancer:Non Small Cell Lung Cancer
    Drug:Xalkori (crizotinib) (ALK inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    New
    Source:
    ScienceDirect
    Title:

    Multiplexed deep sequencing analysis of ALK kinase domain identifies resistance mutations in relapsed patients following crizotinib treatment

    Excerpt:
    ...genomic DNA analysis from thirteen relapsed patients revealed three known crizotinib resistance mutations, C1156Y, L1196M and G1269A.
    DOI:
    10.1016/j.ygeno.2013.02.006
    Evidence Level:
    Resistant: C3 – Early Trials
    New
    Source:
    Transl Cancer Res
    Title:

    Molecular resistance mechanisms of ALK inhibitors and implications for therapeutic management of ALK-rearranged lung cancer patients

    Excerpt:
    In this study crizotinib resistance mutations were confirmed in 11 (20%, N=51) specimens from biopsy sites that included pleural fluid (31%), liver (22%), and nodal tissue (18%) from 10 patients. L1196M and G1269A mutations represented the most common mutations with a frequency of 7% and 4% of the total mutations detected, respectively.
    DOI:
    10.21037/tcr.2017.03.22
    Evidence Level:
    Resistant: C4 – Case Studies
    New
    Source:
    PLoS One
    Title:

    Genomic Aberrations in Crizotinib Resistant Lung Adenocarcinoma Samples Identified by Transcriptome Sequencing

    Excerpt:
    In addition, we observed an G1269A ALK mutation in the post-treatment tumor, which was not detectable in the pre-treatment tumor sample using ddPCR. Gain of an ALK mutation most likely caused the crizotinib resistance in patients #1 and #3.
    DOI:
    10.1371/journal.pone.0153065